Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 67% less
These brands contain the same active ingredient (Sodium Valproate). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Convules CR is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Oral: Sodium Valproate tablets may be taken once or twice a day, while the syrup should be given in divided doses. Epilepsy: Adults should initially receive 600 mg daily in 2 divided doses, preferably after food, increasing by 200 mg/day at 3-day intervals up to a maximum of 2.5 g daily in divided doses until seizures are controlled. The usual maintenance dose is 1-2 g daily (20-30 mg/kg daily). For children over 20 kg, the initial dose is 400 mg daily in divided doses, increased until control is achieved (usually within the range of 20-30 mg/kg daily), up to a maximum of 35 mg/kg daily. For children up to 20 kg, the initial dose is 20 mg/kg daily in divided doses. Febrile convulsion: 20-30 mg/kg/day in 3 divided doses. Bipolar disorder: Initially 600 mg daily (20-30 mg/kg/day) in 2-3 divided doses. The maintenance dosage is 1000-2000 mg daily. Prophylaxis of migraine: 400-600 mg daily, although some patients may require 1000-1500 mg daily. Injection: In adults, a slow intravenous injection may be given over 3-5 minutes, usually 400-800 mg depending on body weight (up to 10 mg/kg), followed by continuous or repeated infusion up to a maximum of 2500 mg/day. In children, the initial dose is 20-30 mg/kg/day, up to a maximum of 40 mg/kg/day. It may be given by direct slow intravenous injection or by infusion using compatible diluents such as 0.9% Sodium Chloride injection or 5% Dextrose injection.
Side Effects
Anorexia, nausea and vomiting are the most common side effects, though enteric coated tablets help minimize them. Sedation, ataxia and tremor can affect the CNS; these occur infrequently and usually ease with a lower dose. Rash, alopecia and increased appetite have been seen occasionally. Valepi Vaiproate also affects liver function: up to 40% of patients show raised liver enzymes, often without symptoms in the first few months of therapy. Rarely, a fatal fulminant hepatitis may develop. Children under 2 years of age with other medical conditions, and those taking multiple antiepileptic agents, are especially prone to hepatic injury, and acute pancreatitis and hyperammonemia have also been frequently associated with Valepi use.
Cautions & Contraindications
Warnings & Precautions
Liver function should be checked before starting treatment and monitored during the first 6 months, particularly in patients at highest risk. Before starting therapy and before any major surgery, it must be confirmed that there is no undue potential for bleeding. Care is needed in patients with renal impairment, during pregnancy and breast-feeding, and in those with systemic lupus erythematosus. Valepi is partly eliminated in the urine as a ketone metabolite, which may cause a false result on urine ketone tests. Treatment should not be stopped suddenly. Valepi should not be used during pregnancy or in women of childbearing potential.
Contraindications
Sodium Valproate is contraindicated to patients who have known hypersensitivity to the drug and liver dysfunction. Use of Sodium Valproate is restricted during pregnancy and in women of childbearing potential.